JP2019162140A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019162140A5 JP2019162140A5 JP2019099850A JP2019099850A JP2019162140A5 JP 2019162140 A5 JP2019162140 A5 JP 2019162140A5 JP 2019099850 A JP2019099850 A JP 2019099850A JP 2019099850 A JP2019099850 A JP 2019099850A JP 2019162140 A5 JP2019162140 A5 JP 2019162140A5
- Authority
- JP
- Japan
- Prior art keywords
- region
- class
- crispr
- polynucleotide
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091033409 CRISPR Proteins 0.000 claims 131
- 210000004027 cell Anatomy 0.000 claims 94
- 238000000034 method Methods 0.000 claims 74
- 230000008685 targeting Effects 0.000 claims 49
- 108020004414 DNA Proteins 0.000 claims 47
- 102000053602 DNA Human genes 0.000 claims 47
- 230000000694 effects Effects 0.000 claims 44
- 102000040430 polynucleotide Human genes 0.000 claims 43
- 108091033319 polynucleotide Proteins 0.000 claims 43
- 239000002157 polynucleotide Substances 0.000 claims 43
- 230000004913 activation Effects 0.000 claims 41
- 229920002477 rna polymer Polymers 0.000 claims 41
- 230000003213 activating effect Effects 0.000 claims 35
- 102000039446 nucleic acids Human genes 0.000 claims 35
- 108020004707 nucleic acids Proteins 0.000 claims 35
- 150000007523 nucleic acids Chemical class 0.000 claims 35
- 238000010354 CRISPR gene editing Methods 0.000 claims 23
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 16
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims 14
- 125000005600 alkyl phosphonate group Chemical group 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 13
- 229920001184 polypeptide Polymers 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims 13
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 12
- ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical compound NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 claims 12
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 11
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims 11
- 101710163270 Nuclease Proteins 0.000 claims 10
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims 10
- 230000000295 complement effect Effects 0.000 claims 9
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 claims 8
- 238000000338 in vitro Methods 0.000 claims 8
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 claims 8
- -1 phosphinates Chemical class 0.000 claims 8
- 108091026890 Coding region Proteins 0.000 claims 7
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 7
- 230000001580 bacterial effect Effects 0.000 claims 7
- 238000004520 electroporation Methods 0.000 claims 7
- 239000013604 expression vector Substances 0.000 claims 7
- 230000002538 fungal effect Effects 0.000 claims 7
- 210000005260 human cell Anatomy 0.000 claims 7
- 150000002632 lipids Chemical class 0.000 claims 7
- 238000001638 lipofection Methods 0.000 claims 7
- 239000002502 liposome Substances 0.000 claims 7
- 210000004962 mammalian cell Anatomy 0.000 claims 7
- 238000000520 microinjection Methods 0.000 claims 7
- 108020001507 fusion proteins Proteins 0.000 claims 6
- 102000037865 fusion proteins Human genes 0.000 claims 6
- 230000035897 transcription Effects 0.000 claims 6
- 238000013518 transcription Methods 0.000 claims 6
- 125000004103 aminoalkyl group Chemical group 0.000 claims 5
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 claims 5
- 150000008298 phosphoramidates Chemical class 0.000 claims 5
- 230000001105 regulatory effect Effects 0.000 claims 5
- 108010061100 Nucleoproteins Proteins 0.000 claims 4
- 102000011931 Nucleoproteins Human genes 0.000 claims 4
- 108700026244 Open Reading Frames Proteins 0.000 claims 3
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims 2
- 108060004795 Methyltransferase Proteins 0.000 claims 2
- 230000033616 DNA repair Effects 0.000 claims 1
- 108010046331 Deoxyribodipyrimidine photo-lyase Proteins 0.000 claims 1
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 claims 1
- 102100034343 Integrase Human genes 0.000 claims 1
- 108010061833 Integrases Proteins 0.000 claims 1
- 102000003960 Ligases Human genes 0.000 claims 1
- 108090000364 Ligases Proteins 0.000 claims 1
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 claims 1
- 102000016397 Methyltransferase Human genes 0.000 claims 1
- 230000010718 Oxidation Activity Effects 0.000 claims 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 108091093078 Pyrimidine dimer Proteins 0.000 claims 1
- 102000018120 Recombinases Human genes 0.000 claims 1
- 108010091086 Recombinases Proteins 0.000 claims 1
- 102000008579 Transposases Human genes 0.000 claims 1
- 108010020764 Transposases Proteins 0.000 claims 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims 1
- 102000005421 acetyltransferase Human genes 0.000 claims 1
- 108020002494 acetyltransferase Proteins 0.000 claims 1
- 230000002730 additional effect Effects 0.000 claims 1
- 230000006154 adenylylation Effects 0.000 claims 1
- 230000029936 alkylation Effects 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000000254 damaging effect Effects 0.000 claims 1
- 230000009615 deamination Effects 0.000 claims 1
- 238000006481 deamination reaction Methods 0.000 claims 1
- 230000006114 demyristoylation Effects 0.000 claims 1
- 230000027832 depurination Effects 0.000 claims 1
- 230000029180 desumoylation Effects 0.000 claims 1
- 230000009504 deubiquitination Effects 0.000 claims 1
- IVVMYMCCLPZNRL-UHFFFAOYSA-N hydrazinylphosphonic acid Chemical class NNP(O)(O)=O IVVMYMCCLPZNRL-UHFFFAOYSA-N 0.000 claims 1
- 230000007498 myristoylation Effects 0.000 claims 1
- 150000008299 phosphorodiamidates Chemical class 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 239000013635 pyrimidine dimer Substances 0.000 claims 1
- 230000010741 sumoylation Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562108931P | 2015-01-28 | 2015-01-28 | |
| US62/108,931 | 2015-01-28 | ||
| US201562251548P | 2015-11-05 | 2015-11-05 | |
| US62/251,548 | 2015-11-05 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539643A Division JP6835726B2 (ja) | 2015-01-28 | 2016-01-27 | Ｃｒｉｓｐｒハイブリッドｄｎａ／ｒｎａポリヌクレオチドおよび使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019162140A JP2019162140A (ja) | 2019-09-26 |
| JP2019162140A5 true JP2019162140A5 (enExample) | 2020-04-16 |
| JP7038079B2 JP7038079B2 (ja) | 2022-03-17 |
Family
ID=55361965
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539643A Active JP6835726B2 (ja) | 2015-01-28 | 2016-01-27 | Ｃｒｉｓｐｒハイブリッドｄｎａ／ｒｎａポリヌクレオチドおよび使用方法 |
| JP2019099850A Active JP7038079B2 (ja) | 2015-01-28 | 2019-05-29 | Ｃｒｉｓｐｒハイブリッドｄｎａ／ｒｎａポリヌクレオチドおよび使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539643A Active JP6835726B2 (ja) | 2015-01-28 | 2016-01-27 | Ｃｒｉｓｐｒハイブリッドｄｎａ／ｒｎａポリヌクレオチドおよび使用方法 |
Country Status (27)
| Country | Link |
|---|---|
| US (11) | US9650617B2 (enExample) |
| EP (2) | EP3250691B9 (enExample) |
| JP (2) | JP6835726B2 (enExample) |
| KR (4) | KR20190112855A (enExample) |
| CN (2) | CN107810270A (enExample) |
| AU (3) | AU2016211517B2 (enExample) |
| BR (1) | BR112017016080B1 (enExample) |
| CA (2) | CA3060508C (enExample) |
| DK (1) | DK3250691T5 (enExample) |
| ES (1) | ES2955957T3 (enExample) |
| FI (1) | FI3250691T3 (enExample) |
| GB (1) | GB2550745A (enExample) |
| HR (1) | HRP20231022T1 (enExample) |
| HU (1) | HUE063813T2 (enExample) |
| IL (4) | IL288263B (enExample) |
| LT (1) | LT3250691T (enExample) |
| MX (2) | MX2017009506A (enExample) |
| NZ (1) | NZ733702A (enExample) |
| PL (1) | PL3250691T3 (enExample) |
| PT (1) | PT3250691T (enExample) |
| RS (1) | RS64527B1 (enExample) |
| RU (1) | RU2713328C2 (enExample) |
| SG (3) | SG11201705788TA (enExample) |
| SI (1) | SI3250691T1 (enExample) |
| SM (1) | SMT202300341T1 (enExample) |
| WO (1) | WO2016123230A1 (enExample) |
| ZA (2) | ZA201705174B (enExample) |
Families Citing this family (157)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2013010911A (es) | 2011-03-23 | 2015-03-03 | Pioneer Hi Bred Int | Metodos para producir un locus de rasgo transgenico complejo. |
| EP2734621B1 (en) | 2011-07-22 | 2019-09-04 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US10760064B2 (en) | 2013-03-15 | 2020-09-01 | The General Hospital Corporation | RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci |
| KR102405549B1 (ko) | 2013-03-15 | 2022-06-08 | 더 제너럴 하스피탈 코포레이션 | Rna-안내 게놈 편집을 위해 특이성을 증가시키기 위한 절단된 안내 rna(tru-grnas)의 이용 |
| SMT202100516T1 (it) | 2013-04-16 | 2021-11-12 | Regeneron Pharma | Modificazione mirata del genoma di ratto |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| MX363842B (es) | 2013-08-22 | 2019-04-05 | Du Pont | Métodos para producir modificaciones genéticas en un genoma vegetal sin incorporar un marcador transgénico seleccionable, y composiciones de éstas. |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| BR112016013400B1 (pt) | 2013-12-11 | 2023-02-14 | Regeneron Pharmaceuticals, Inc. | Método in vitro para modificar um genoma em um lócus genômico de interesse em uma célula pluripotente |
| US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
| WO2016022363A2 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| CA2956487A1 (en) | 2014-09-12 | 2016-03-17 | E. I. Du Pont De Nemours And Company | Generation of site-specific-integration sites for complex trait loci in corn and soybean, and methods of use |
| AU2015330699B2 (en) | 2014-10-10 | 2021-12-02 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| GB201418965D0 (enExample) | 2014-10-24 | 2014-12-10 | Ospedale San Raffaele And Fond Telethon | |
| CA2963820A1 (en) | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
| LT3250691T (lt) | 2015-01-28 | 2023-09-11 | Caribou Biosciences, Inc. | Crispr hibridiniai dnr/rnr polinukleotidai ir naudojimo būdai |
| CN107567499A (zh) | 2015-03-27 | 2018-01-09 | 纳幕尔杜邦公司 | 大豆u6核小rna基因启动子及其在植物小rna基因的组成型表达中的用途 |
| GB201506509D0 (en) | 2015-04-16 | 2015-06-03 | Univ Wageningen | Nuclease-mediated genome editing |
| US11390884B2 (en) | 2015-05-11 | 2022-07-19 | Editas Medicine, Inc. | Optimized CRISPR/cas9 systems and methods for gene editing in stem cells |
| CN116334142A (zh) | 2015-06-09 | 2023-06-27 | 爱迪塔斯医药公司 | 用于改善移植的crispr/cas相关方法和组合物 |
| US20160362667A1 (en) * | 2015-06-10 | 2016-12-15 | Caribou Biosciences, Inc. | CRISPR-Cas Compositions and Methods |
| US9790490B2 (en) * | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| US10648020B2 (en) | 2015-06-18 | 2020-05-12 | The Broad Institute, Inc. | CRISPR enzymes and systems |
| AU2016285724A1 (en) | 2015-06-29 | 2017-11-16 | Ionis Pharmaceuticals, Inc. | Modified CRISPR RNA and modified single CRISPR RNA and uses thereof |
| US11279928B2 (en) | 2015-06-29 | 2022-03-22 | Massachusetts Institute Of Technology | Compositions comprising nucleic acids and methods of using the same |
| US9926546B2 (en) | 2015-08-28 | 2018-03-27 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases |
| US9512446B1 (en) | 2015-08-28 | 2016-12-06 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases |
| WO2017053879A1 (en) | 2015-09-24 | 2017-03-30 | Editas Medicine, Inc. | Use of exonucleases to improve crispr/cas-mediated genome editing |
| WO2017070598A1 (en) | 2015-10-23 | 2017-04-27 | Caribou Biosciences, Inc. | Engineered crispr class 2 cross-type nucleic-acid targeting nucleic acids |
| IL294014B2 (en) | 2015-10-23 | 2024-07-01 | Harvard College | Nucleobase editors and uses thereof |
| RU2018117360A (ru) * | 2015-12-04 | 2020-01-09 | Карибо Биосайенсиз, Инк. | Сконструированные нуклеиновые кислоты, нацеленные на нуклеиновую кислоту |
| BR112018011503A2 (pt) | 2015-12-07 | 2018-12-04 | Zymergen Inc | promotores da corynebacterium glutamicum |
| US9988624B2 (en) | 2015-12-07 | 2018-06-05 | Zymergen Inc. | Microbial strain improvement by a HTP genomic engineering platform |
| CN109310784B (zh) | 2015-12-07 | 2022-08-19 | 阿克生物公司 | 用于制备和使用指导核酸的方法和组合物 |
| US11208649B2 (en) | 2015-12-07 | 2021-12-28 | Zymergen Inc. | HTP genomic engineering platform |
| WO2017136794A1 (en) | 2016-02-03 | 2017-08-10 | Massachusetts Institute Of Technology | Structure-guided chemical modification of guide rna and its applications |
| US9896696B2 (en) * | 2016-02-15 | 2018-02-20 | Benson Hill Biosystems, Inc. | Compositions and methods for modifying genomes |
| WO2017165826A1 (en) | 2016-03-25 | 2017-09-28 | Editas Medicine, Inc. | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use |
| WO2017180694A1 (en) | 2016-04-13 | 2017-10-19 | Editas Medicine, Inc. | Cas9 fusion molecules gene editing systems, and methods of use thereof |
| US12410416B2 (en) | 2016-04-19 | 2025-09-09 | The Broad Institute, Inc. | CRISPR enzymes and systems with modified pam specificity |
| CN106244591A (zh) * | 2016-08-23 | 2016-12-21 | 苏州吉玛基因股份有限公司 | 修饰crRNA在CRISPR/Cpf1基因编辑系统中的应用 |
| EA201892810A1 (ru) | 2016-06-01 | 2019-06-28 | Квс Заат Се | Гибридные последовательности нуклеиновых кислот для геномной инженерии |
| US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
| EP3478833A4 (en) | 2016-06-30 | 2019-10-02 | Zymergen, Inc. | METHOD FOR PRODUCING A BACTERIAL HEMOGLOBIN LIBRARY AND ITS USE |
| JP2019519241A (ja) | 2016-06-30 | 2019-07-11 | ザイマージェン インコーポレイテッド | グルコース透過酵素ライブラリーを生成するための方法およびその使用 |
| US11845929B2 (en) | 2016-07-08 | 2023-12-19 | Ohio State Innovation Foundation | Modified nucleic acids, hybrid guide RNAs, and uses thereof |
| WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| CN109804066A (zh) | 2016-08-09 | 2019-05-24 | 哈佛大学的校长及成员们 | 可编程cas9-重组酶融合蛋白及其用途 |
| US20190264193A1 (en) | 2016-08-12 | 2019-08-29 | Caribou Biosciences, Inc. | Protein engineering methods |
| SG11201901306XA (en) | 2016-08-19 | 2019-03-28 | Toolgen Inc | Artificially engineered angiogenesis regulatory system |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| US11306305B2 (en) | 2016-09-23 | 2022-04-19 | Board Of Trustees Of Southern Illinois University | Tuning CRISPR/Cas9 activity with chemically modified nucleotide substitutions |
| EP3523427A4 (en) | 2016-10-07 | 2020-09-02 | Integrated DNA Technologies, Inc. | S. PYOGENES AND POLYPEPTIDES MUTANT CAS9 GENES CODED BY SUCH GENES |
| US11242542B2 (en) | 2016-10-07 | 2022-02-08 | Integrated Dna Technologies, Inc. | S. pyogenes Cas9 mutant genes and polypeptides encoded by same |
| CN110214180A (zh) | 2016-10-14 | 2019-09-06 | 哈佛大学的校长及成员们 | 核碱基编辑器的aav递送 |
| US20180282722A1 (en) * | 2016-11-21 | 2018-10-04 | Massachusetts Institute Of Technology | Chimeric DNA:RNA Guide for High Accuracy Cas9 Genome Editing |
| WO2018098383A1 (en) | 2016-11-22 | 2018-05-31 | Integrated Dna Technologies, Inc. | Crispr/cpf1 systems and methods |
| US9816093B1 (en) | 2016-12-06 | 2017-11-14 | Caribou Biosciences, Inc. | Engineered nucleic acid-targeting nucleic acids |
| WO2018111947A1 (en) | 2016-12-12 | 2018-06-21 | Integrated Dna Technologies, Inc. | Genome editing enhancement |
| EP3555297A1 (en) | 2016-12-19 | 2019-10-23 | Editas Medicine, Inc. | Assessing nuclease cleavage |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| US20190382751A1 (en) * | 2016-12-28 | 2019-12-19 | Ionis Pharmaceuticals, Inc. | Modified crispr rna and uses thereof |
| WO2018129368A2 (en) | 2017-01-06 | 2018-07-12 | Editas Medicine, Inc. | Methods of assessing nuclease cleavage |
| EP3574101B1 (en) * | 2017-01-30 | 2023-04-19 | KWS SAAT SE & Co. KGaA | Repair template linkage to endonucleases for genome engineering |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| WO2018165631A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Cancer vaccine |
| JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
| KR20240116572A (ko) | 2017-03-23 | 2024-07-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
| CA3084252A1 (en) | 2017-03-28 | 2018-10-04 | Caribou Biosciences, Inc. | Crispr-associated (cas) protein |
| WO2018201086A1 (en) | 2017-04-28 | 2018-11-01 | Editas Medicine, Inc. | Methods and systems for analyzing guide rna molecules |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| CN108977442B (zh) * | 2017-06-05 | 2023-01-06 | 广州市锐博生物科技有限公司 | 用于dna编辑的系统及其应用 |
| EP3635113A4 (en) | 2017-06-05 | 2021-03-17 | Fred Hutchinson Cancer Research Center | SAFE GENOMIC HAVERS FOR GENETIC THERAPIES IN HUMAN STEM CELLS AND NANOPARTICLES MODIFIED TO ENABLE TARGETED GENETIC THERAPIES |
| JP2020524490A (ja) | 2017-06-06 | 2020-08-20 | ザイマージェン インコーポレイテッド | Ｅｓｃｈｅｒｉｃｈｉａ Ｃｏｌｉを改良するためのＨＴＰゲノム操作プラットフォーム |
| EP3635112A2 (en) | 2017-06-06 | 2020-04-15 | Zymergen, Inc. | A htp genomic engineering platform for improving fungal strains |
| EP3635114B1 (en) * | 2017-06-07 | 2024-11-06 | Arc Bio, LLC | Creation and use of guide nucleic acids |
| KR102746733B1 (ko) | 2017-06-09 | 2024-12-24 | 에디타스 메디신, 인코포레이티드 | 조작된 cas9 뉴클레아제 |
| US10907150B2 (en) | 2017-06-14 | 2021-02-02 | Wisconsin Alumni Research Foundation | Modified guide RNAs, CRISPR-ribonucleotprotein complexes and methods of use |
| WO2019014564A1 (en) | 2017-07-14 | 2019-01-17 | Editas Medicine, Inc. | SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES |
| CN112501254B (zh) | 2017-07-14 | 2024-07-19 | 上海吐露港生物科技有限公司 | 一种Cas蛋白的用途及靶标核酸分子的检测方法和试剂盒 |
| US11584955B2 (en) * | 2017-07-14 | 2023-02-21 | Shanghai Tolo Biotechnology Company Limited | Application of Cas protein, method for detecting target nucleic acid molecule and kit |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| EP3665279B1 (en) | 2017-08-09 | 2023-07-19 | Benson Hill, Inc. | Compositions and methods for modifying genomes |
| US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
| WO2019046540A1 (en) | 2017-08-31 | 2019-03-07 | New York Genome Center, Inc. | METHODS AND COMPOSITIONS COMPRISING CRISPR-CPF1 AND APPROVED GUIDING CRISPR RNAES FOR PROGRAMMABLE GENOMIC DELETIONS |
| CN111757937A (zh) | 2017-10-16 | 2020-10-09 | 布罗德研究所股份有限公司 | 腺苷碱基编辑器的用途 |
| WO2019099943A1 (en) | 2017-11-16 | 2019-05-23 | Astrazeneca Ab | Compositions and methods for improving the efficacy of cas9-based knock-in strategies |
| WO2019113132A1 (en) | 2017-12-05 | 2019-06-13 | Caribou Biosciences, Inc. | Modified lymphocytes |
| EP3724216A1 (en) | 2017-12-15 | 2020-10-21 | Dana Farber Cancer Institute, Inc. | Stabilized peptide-mediated targeted protein degradation |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| WO2019147743A1 (en) * | 2018-01-26 | 2019-08-01 | Massachusetts Institute Of Technology | Structure-guided chemical modification of guide rna and its applications |
| WO2019152941A1 (en) | 2018-02-05 | 2019-08-08 | Caribou Biosciences, Inc. | Engineered gut microbes for reduction of reactivation of detoxified drugs |
| US12084676B2 (en) | 2018-02-23 | 2024-09-10 | Pioneer Hi-Bred International, Inc. | Cas9 orthologs |
| WO2019173248A1 (en) | 2018-03-07 | 2019-09-12 | Caribou Biosciences, Inc. | Engineered nucleic acid-targeting nucleic acids |
| JP7555822B2 (ja) | 2018-04-19 | 2024-09-25 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | ゲノム編集のための組成物および方法 |
| GB2589246A (en) | 2018-05-16 | 2021-05-26 | Synthego Corp | Methods and systems for guide RNA design and use |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| US12227776B2 (en) | 2018-06-13 | 2025-02-18 | Caribou Biosciences, Inc. | Engineered cascade components and cascade complexes |
| CA3102148A1 (en) * | 2018-06-13 | 2019-12-19 | Caribou Biosciences, Inc. | Engineered cascade components and cascade complexes |
| US10227576B1 (en) | 2018-06-13 | 2019-03-12 | Caribou Biosciences, Inc. | Engineered cascade components and cascade complexes |
| US12338436B2 (en) | 2018-06-29 | 2025-06-24 | Editas Medicine, Inc. | Synthetic guide molecules, compositions and methods relating thereto |
| EP3820495A4 (en) | 2018-07-09 | 2022-07-20 | The Broad Institute Inc. | RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES |
| JP7649735B2 (ja) | 2018-09-07 | 2025-03-21 | アストラゼネカ・アクチエボラーグ | 改善されたヌクレアーゼのための組成物及び方法 |
| DK3833682T3 (da) | 2018-10-01 | 2022-10-03 | Caribou Biosciences Inc | Selvmordsmolekyle sammensætninger og fremgangsmåder |
| KR102126573B1 (ko) | 2018-10-18 | 2020-06-26 | 대한민국 | CRISPR-Cas9 시스템을 이용한 유색고약버섯의 리그닌 분해효소의 유전자 편집방법 및 이의 용도 |
| US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
| KR20210088615A (ko) * | 2018-10-31 | 2021-07-14 | 지머젠 인코포레이티드 | Dna 라이브러리의 다중 결정적 어셈블리 |
| US11739320B2 (en) | 2018-11-05 | 2023-08-29 | Wisconsin Alumni Research Foundation | Gene correction of Pompe disease and other autosomal recessive disorders via RNA-guided nucleases |
| EP3894550A4 (en) | 2018-12-14 | 2023-01-04 | Pioneer Hi-Bred International, Inc. | NOVEL CRISPR-CAS SYSTEMS FOR GENOME EDITING |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| GB2597377A (en) * | 2019-01-25 | 2022-01-26 | Synthego Corp | Systems and methods for modulating CRISPR activity |
| WO2020176389A1 (en) | 2019-02-25 | 2020-09-03 | Caribou Biosciences, Inc. | Plasmids for gene editing |
| KR20210136997A (ko) | 2019-03-08 | 2021-11-17 | 지머젠 인코포레이티드 | 미생물에서 반복적 게놈 편집 |
| US11053515B2 (en) | 2019-03-08 | 2021-07-06 | Zymergen Inc. | Pooled genome editing in microbes |
| CA3130488A1 (en) | 2019-03-19 | 2020-09-24 | David R. Liu | Methods and compositions for editing nucleotide sequences |
| US10982187B2 (en) | 2019-03-26 | 2021-04-20 | Genus Plc | Bos taurus variety ‘HO840003150607238’ and methods of use thereof |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US10975351B2 (en) | 2019-06-17 | 2021-04-13 | Abs Global, Inc. | Bos taurus variety ‘JE840003146074527’ and methods of use therof |
| CA3153301A1 (en) * | 2019-09-05 | 2021-03-11 | Benson Hill, Inc. | Compositions and methods for modifying genomes |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| US20230002761A1 (en) | 2019-11-19 | 2023-01-05 | Benson Hill, Inc. | Anti-bacterial crispr compositions and methods |
| EP4028521A1 (en) | 2019-12-09 | 2022-07-20 | Caribou Biosciences, Inc. | Crispr abasic restricted nucleotides and crispr accuracy via analogs |
| CA3166430A1 (en) * | 2020-02-05 | 2021-08-12 | Ryan T. Gill | Compositions and methods for targeting, editing or modifying human genes |
| US20230087228A1 (en) * | 2020-02-24 | 2023-03-23 | The Broad Institute, Inc. | Novel type iv and type i crispr-cas systems and methods of use thereof |
| US20230340538A1 (en) | 2020-04-08 | 2023-10-26 | Astrazeneca Ab | Compositions and methods for improved site-specific modification |
| WO2021226558A1 (en) | 2020-05-08 | 2021-11-11 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| CN115956120A (zh) * | 2020-05-12 | 2023-04-11 | 马萨诸塞大学 | 用于crispr基因组编辑的修饰的指导rna |
| US20250027078A1 (en) * | 2020-10-19 | 2025-01-23 | Caribou Biosciences, Inc. | Dna-containing polynucleotides and guides for crispr type v systems, and methods of making and using the same |
| CN112301162B (zh) * | 2020-10-22 | 2023-09-22 | 清华-伯克利深圳学院筹备办公室 | 同时检测dna病毒和rna病毒的病毒核酸检测方法 |
| US20240182890A1 (en) | 2021-04-07 | 2024-06-06 | Astrazeneca Ab | Compositions and methods for site-specific modification |
| GB202509407D0 (en) * | 2021-09-22 | 2025-07-30 | Verve Therapeutics Inc | Gene editing of pcsk9 or angptl3 and compositions and methods of using same for treatment of disease |
| EP4408996A2 (en) | 2021-09-30 | 2024-08-07 | Astrazeneca AB | Use of inhibitors to increase efficiency of crispr/cas insertions |
| CN117999481A (zh) | 2021-10-26 | 2024-05-07 | 卡里布生物科学公司 | 核酸外切酶偶联实时核酸内切酶活性测定 |
| IL312921A (en) * | 2021-12-07 | 2024-07-01 | Caribou Biosciences Inc | A method for capturing CRISPR endonuclease cleavage products |
| EP4499829A2 (en) * | 2022-03-29 | 2025-02-05 | Accuredit Therapeutics (Suzhou) Co., Ltd. | Compositions and methods for treatment of transthyretin amyloidosis |
| KR20250005083A (ko) * | 2022-04-13 | 2025-01-09 | 카리부 바이오사이언시스 인코포레이티드 | Crispr v형 시스템의 치료학적 응용 |
| WO2023224327A1 (ko) * | 2022-05-20 | 2023-11-23 | 한국생명공학연구원 | 오토라이신을 활용한 미세조류의 유전자 교정 효율을 증대시키기 위한 시스템 및 방법 |
| EP4504764A1 (en) | 2022-05-26 | 2025-02-12 | Caribou Biosciences, Inc. | Cytokine-receptor fusions for immune cell stimulation |
| WO2023240042A1 (en) | 2022-06-06 | 2023-12-14 | Caribou Biosciences, Inc. | Treatment of autoimmune diseases with engineered immune cells |
| EP4578945A4 (en) | 2022-08-26 | 2025-12-17 | Guangzhou Reforgene Medicine Co Ltd | CRISPR-CAS13 SYSTEM AND ITS USE |
| IL319598A (en) | 2022-09-30 | 2025-05-01 | Caribou Biosciences Inc | Anti-ROR1 chimeric antigen receptors, CAR-NK cells and related methods |
| EP4584283A1 (en) | 2022-11-14 | 2025-07-16 | Caribou Biosciences, Inc. | Anti-cll-1 chimeric antigen receptors, engineered cells and related methods |
| EP4414452A1 (en) * | 2023-02-13 | 2024-08-14 | Universidad de Granada | Dual-guide rna composition for executing a single-guide rna crispr-associated system |
| WO2024201368A1 (en) | 2023-03-29 | 2024-10-03 | Astrazeneca Ab | Use of inhibitors to increase efficiency of crispr/cas insertions |
| AU2024265453A1 (en) | 2023-05-01 | 2025-09-25 | Caribou Biosciences, Inc. | Treatment of autoimmune diseases with bcma-targeting engineered immune cells |
| AU2024270764A1 (en) | 2023-05-15 | 2025-12-04 | Nchroma Bio, Inc. | Compositions and methods for epigenetic regulation of hbv gene expression |
| WO2025006880A1 (en) | 2023-06-29 | 2025-01-02 | Caribou Biosciences, Inc. | Diagnostic and therapeutic methods for use with ror1 antagonists |
| WO2025024676A1 (en) | 2023-07-26 | 2025-01-30 | Caribou Biosciences, Inc. | In vitro validation methods for cd19-targeting cell therapies |
| CN119614679A (zh) * | 2023-09-14 | 2025-03-14 | 厦门大学 | 一款通用型核酸检测平台 |
| WO2025064930A1 (en) * | 2023-09-20 | 2025-03-27 | Emory University | Nucleic acid hairpin based triggered hydrogels and uses thereof |
| WO2025117745A1 (en) | 2023-12-01 | 2025-06-05 | Caribou Biosciences, Inc. | Methods and compositions for improving precision of endonuclease-mediated genome editing |
| WO2025193609A1 (en) | 2024-03-11 | 2025-09-18 | Caribou Biosciences, Inc. | Methods and compositions for cost-effective assessment of nucleic acid transcripts and isoforms in cells |
| WO2025193386A1 (en) | 2024-03-13 | 2025-09-18 | Caribou Biosciences, Inc. | Treatment regimens for autoimmune disease with cd19-targeting engineered immune cells |
| WO2026024468A1 (en) | 2024-07-26 | 2026-01-29 | Caribou Biosciences, Inc. | Modular linked chimeric antigen receptors |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
| US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
| US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| AU7979491A (en) | 1990-05-03 | 1991-11-27 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
| US7256322B2 (en) | 1999-10-01 | 2007-08-14 | Pioneer Hi-Bred International, Inc. | Wuschel (WUS) Gene Homologs |
| AU2005210493B2 (en) | 2004-02-02 | 2009-06-04 | Pioneer Hi-Bred International, Inc. | AP2 domain transcription factor ODP2 (ovule development protein 2) and methods of use |
| ES2541693T3 (es) * | 2007-03-02 | 2015-07-23 | Dupont Nutrition Biosciences Aps | Cultivos con resistencia mejorada a fagos |
| CN103038338B (zh) | 2010-05-10 | 2017-03-08 | 加利福尼亚大学董事会 | 核糖核酸内切酶组合物及其使用方法 |
| GB201122458D0 (en) | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
| WO2013141680A1 (en) | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
| US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| EP4570908A3 (en) * | 2012-05-25 | 2025-10-22 | The Regents of the University of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| ES2757623T3 (es) | 2012-07-25 | 2020-04-29 | Broad Inst Inc | Proteínas de unión a ADN inducibles y herramientas de perturbación genómica y aplicaciones de las mismas |
| PT2784162E (pt) | 2012-12-12 | 2015-08-27 | Broad Inst Inc | Engenharia de sistemas, métodos e composições guia otimizadas para a manipulação de sequências |
| EP2784162B1 (en) | 2012-12-12 | 2015-04-08 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| WO2014093595A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
| DK3064585T3 (da) | 2012-12-12 | 2020-04-27 | Broad Inst Inc | Konstruering og optimering af forbedrede systemer, fremgangsmåder og enzymsammensætninger til sekvensmanipulation |
| WO2014093701A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| WO2014093622A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
| DK2931898T3 (en) | 2012-12-12 | 2016-06-20 | Massachusetts Inst Technology | CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS |
| EP2971167B1 (en) | 2013-03-14 | 2019-07-31 | Caribou Biosciences, Inc. | Compositions and methods of nucleic acid-targeting nucleic acids |
| KR102405549B1 (ko) * | 2013-03-15 | 2022-06-08 | 더 제너럴 하스피탈 코포레이션 | Rna-안내 게놈 편집을 위해 특이성을 증가시키기 위한 절단된 안내 rna(tru-grnas)의 이용 |
| AU2014281026B2 (en) * | 2013-06-17 | 2020-05-28 | Massachusetts Institute Of Technology | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation |
| MX363842B (es) * | 2013-08-22 | 2019-04-05 | Du Pont | Métodos para producir modificaciones genéticas en un genoma vegetal sin incorporar un marcador transgénico seleccionable, y composiciones de éstas. |
| WO2015089277A1 (en) * | 2013-12-12 | 2015-06-18 | The Regents Of The University Of California | Methods and compositions for modifying a single stranded target nucleic acid |
| LT3250691T (lt) | 2015-01-28 | 2023-09-11 | Caribou Biosciences, Inc. | Crispr hibridiniai dnr/rnr polinukleotidai ir naudojimo būdai |
-
2016
- 2016-01-27 LT LTEPPCT/US2016/015145T patent/LT3250691T/lt unknown
- 2016-01-27 EP EP16704978.2A patent/EP3250691B9/en active Active
- 2016-01-27 PT PT167049782T patent/PT3250691T/pt unknown
- 2016-01-27 WO PCT/US2016/015145 patent/WO2016123230A1/en not_active Ceased
- 2016-01-27 CN CN201680007759.XA patent/CN107810270A/zh active Pending
- 2016-01-27 SM SM20230341T patent/SMT202300341T1/it unknown
- 2016-01-27 SI SI201631744T patent/SI3250691T1/sl unknown
- 2016-01-27 MX MX2017009506A patent/MX2017009506A/es unknown
- 2016-01-27 CN CN202010419105.6A patent/CN111518811A/zh active Pending
- 2016-01-27 KR KR1020197028425A patent/KR20190112855A/ko not_active Ceased
- 2016-01-27 ES ES16704978T patent/ES2955957T3/es active Active
- 2016-01-27 EP EP23176464.8A patent/EP4257690A3/en active Pending
- 2016-01-27 RU RU2017130143A patent/RU2713328C2/ru active
- 2016-01-27 IL IL288263A patent/IL288263B/en unknown
- 2016-01-27 RS RS20230746A patent/RS64527B1/sr unknown
- 2016-01-27 BR BR112017016080-3A patent/BR112017016080B1/pt active IP Right Grant
- 2016-01-27 KR KR1020177023452A patent/KR20170126875A/ko not_active Ceased
- 2016-01-27 US US15/008,054 patent/US9650617B2/en active Active
- 2016-01-27 AU AU2016211517A patent/AU2016211517B2/en active Active
- 2016-01-27 DK DK16704978.2T patent/DK3250691T5/da active
- 2016-01-27 SG SG11201705788TA patent/SG11201705788TA/en unknown
- 2016-01-27 PL PL16704978.2T patent/PL3250691T3/pl unknown
- 2016-01-27 FI FIEP16704978.2T patent/FI3250691T3/fi active
- 2016-01-27 JP JP2017539643A patent/JP6835726B2/ja active Active
- 2016-01-27 SG SG10201906513WA patent/SG10201906513WA/en unknown
- 2016-01-27 HR HRP20231022TT patent/HRP20231022T1/hr unknown
- 2016-01-27 NZ NZ733702A patent/NZ733702A/en unknown
- 2016-01-27 KR KR1020227040706A patent/KR20220159498A/ko not_active Ceased
- 2016-01-27 CA CA3060508A patent/CA3060508C/en active Active
- 2016-01-27 GB GB1712504.8A patent/GB2550745A/en not_active Withdrawn
- 2016-01-27 HU HUE16704978A patent/HUE063813T2/hu unknown
- 2016-01-27 KR KR1020197001414A patent/KR102319192B1/ko active Active
- 2016-01-27 CA CA2975166A patent/CA2975166C/en active Active
- 2016-01-27 SG SG10201804715WA patent/SG10201804715WA/en unknown
- 2016-08-16 US US15/238,464 patent/US9580701B2/en active Active
-
2017
- 2017-01-18 US US15/408,920 patent/US9688972B2/en active Active
- 2017-04-21 US US15/493,744 patent/US9771601B2/en active Active
- 2017-07-20 MX MX2024015281A patent/MX2024015281A/es unknown
- 2017-07-23 IL IL253608A patent/IL253608B/en active IP Right Grant
- 2017-07-31 ZA ZA2017/05174A patent/ZA201705174B/en unknown
- 2017-08-17 US US15/679,555 patent/US9868962B2/en active Active
- 2017-12-18 US US15/845,524 patent/US10519468B2/en active Active
-
2018
- 2018-06-13 ZA ZA2018/03945A patent/ZA201803945B/en unknown
- 2018-10-02 IL IL262042A patent/IL262042B/en active IP Right Grant
-
2019
- 2019-05-29 JP JP2019099850A patent/JP7038079B2/ja active Active
- 2019-10-31 US US16/670,832 patent/US11236364B2/en active Active
-
2020
- 2020-03-08 IL IL273147A patent/IL273147B/en unknown
- 2020-07-28 US US16/941,130 patent/US10988781B2/en active Active
-
2021
- 2021-03-22 US US17/208,146 patent/US11459588B2/en active Active
- 2021-05-07 AU AU2021202913A patent/AU2021202913B2/en active Active
-
2022
- 2022-08-15 US US17/888,027 patent/US20230193324A1/en active Pending
-
2023
- 2023-04-04 AU AU2023202056A patent/AU2023202056B2/en active Active
-
2025
- 2025-01-10 US US19/016,766 patent/US20250376700A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019162140A5 (enExample) | ||
| AU2023241391B2 (en) | Novel crispr enzymes and systems | |
| JP2018503386A5 (enExample) | ||
| US20240132877A1 (en) | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use | |
| US20240167060A1 (en) | Compositions and methods for genomic editing by insertion of donor polynucleotides | |
| US20230026726A1 (en) | Crispr/cas-related methods and compositions for treating sickle cell disease | |
| AU2017252023B2 (en) | Materials and methods for treatment of hemoglobinopathies | |
| AU2022287660B2 (en) | Rapamycin resistant cells | |
| CN110662838B (zh) | 用于基因编辑的组合物和方法 | |
| US10526590B2 (en) | Compounds and methods for CRISPR/Cas-based genome editing by homologous recombination | |
| US20190048337A1 (en) | Crispr/Cas-Related Methods and Compositions for Treating Duchenne Muscular Dystrophy and Becker | |
| CN110914289A (zh) | 用于工程化细胞的材料和方法及其在免疫肿瘤学中的用途 | |
| CN112424348A (zh) | 新颖的rna-可编程的内切核酸酶系统及其用途 | |
| WO2015148860A1 (en) | Crispr/cas-related methods and compositions for treating beta-thalassemia | |
| IL288263B (en) | CRISPR DNA/RNA hybrid polynucleotides and methods of using them | |
| CN119095972B (zh) | 基因组编辑的组合物和方法 | |
| CA3127684A1 (en) | Stabilized crispr complexes | |
| US20250332287A1 (en) | Identification of tissue-specific extragenic safe harbors for gene therapy approaches | |
| Misic | Regulation of mtDNA gene expression and the role of respiratory chain supercomplexes in mammalian mitochondria | |
| Rehmanji et al. | of Diatoms | |
| TW202440938A (zh) | 用於抑制微管解聚蛋白2(stmn2)轉錄物中異常剪接的基因編輯方法 | |
| Cheruiyot | Nonsense Mediated RNA Decay Promotes Survival of Cells with Defective Splicing | |
| Polosa et al. | Mechanism and Regulation of Mitochondrial Transcription in Animal Cells | |
| HK40039896A (en) | Nuclease systems for genetic engineering |